test

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer

Conditions

Ovarian Carcinosarcoma | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Uterine Sarcoma | Stage I Uterine Sarcoma | Stage IA Ovarian Epithelial Cancer | Stage IA Primary Peritoneal Cavity Cancer | Stage IB Ovarian Epithelial Cancer | Stage IB Primary Peritoneal Cavity Cancer | Stage IC Ovarian Epithelial Cancer | Stage IC Primary Peritoneal Cavity Cancer | Stage II Uterine Sarcoma | Stage IIA Ovarian Epithelial Cancer | Stage IIA Primary Peritoneal Cavity Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIB Primary Peritoneal Cavity Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IIC Primary Peritoneal Cavity Cancer | Stage III Uterine Sarcoma | Stage IIIA Ovarian Epithelial Cancer | Stage IIIA Primary Peritoneal Cavity Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIB Primary Peritoneal Cavity Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIIC Primary Peritoneal Cavity Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Primary Peritoneal Cavity Cancer | Stage IV Uterine Sarcoma | Uterine Carcinosarcoma

What is the purpose of this trial?

This randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works compared with giving paclitaxel together with ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine, ovarian, fallopian tube, or peritorium cavity cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether paclitaxel is more effective when given together with carboplatin or ifosfamide in treating patients with uterine, ovarian, fallopian tube, or peritorium cavity cancer.



Participation Guidelines

Age:
18 Years - N/A
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Gynecologic Oncology Group
National Cancer Institute (NCI)
Dates:
August 2009
Last Updated:
February 27, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00954174